Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-01 4:54 pm Purchase | 2022-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA | BlackRock Inc. BLK | 3,581,679 5.200% | 15,697 (+0.44%) | Filing |
| 2022-09-08 1:43 pm Purchase | 2022-08-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA | BlackRock Inc. BLK | 3,565,982 5.100% | 82,130 (+2.36%) | Filing |
| 2022-02-14 10:56 am Sale | 2021-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA | AMERIPRISE FINANCIAL INC AMP | 285 0.000% | -2,370,951 (-99.99%) | Filing History |
| 2022-02-10 11:07 am Purchase | 2021-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA | PICTET ASSET MANAGEMENT SA | 3,548,649 5.150% | 3,548,649 (New Position) | Filing History |
| 2022-02-10 08:22 am Purchase | 2021-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA | The Vanguard Group | 2,890,708 8.530% | 354,287 (+13.97%) | Filing History |
| 2022-01-27 5:13 pm Unchanged | 2021-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA | BlackRock Inc. BLK | 3,483,852 10.300% | 0 (Unchanged) | Filing |
| 2022-01-26 09:16 am Sale | 2021-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA | BlackRock Inc. BLK | 3,483,852 10.300% | -34,037 (-0.97%) | Filing |
| 2021-11-24 3:40 pm Unchanged | 2021-10-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA | BlackRock Inc. BLK | 3,517,889 10.400% | 0 (Unchanged) | Filing |
| 2021-11-10 09:43 am Purchase | 2021-10-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA | BlackRock Inc. BLK | 3,517,889 10.400% | 3,517,889 (New Position) | Filing |
| 2021-02-16 4:24 pm Purchase | 2020-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA | HHLR ADVISORS LTD. | 2,920,023 9.200% | 1,024,135 (+54.02%) | Filing History |
| 2021-02-16 1:29 pm Sale | 2020-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA | ArrowMark Colorado Holdings LLC | 1,156,338 3.700% | -118,086 (-9.27%) | Filing History |
| 2021-02-12 12:08 pm Purchase | 2020-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA | AMERIPRISE FINANCIAL INC AMP | 2,371,236 7.500% | 1,221,658 (+106.27%) | Filing History |
| 2021-02-10 11:10 am Purchase | 2020-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA | The Vanguard Group | 2,536,421 8.020% | 1,334,968 (+111.11%) | Filing History |
| 2020-11-05 4:55 pm Sale | 2020-10-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA | Consonance Capital Management LP | 1,252,229 3.990% | -988,550 (-44.12%) | Filing History |
| 2020-07-28 5:29 pm Purchase | 2020-07-21 | 13D | Kiniksa Pharmaceuticals, Ltd. KNSA | BAKER BROS. ADVISORS LP | 2,903,030 9.200% | 6,253 (+0.22%) | Filing History |
| 2020-06-16 09:37 am Purchase | 2020-03-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA | Consonance Capital Management LP | 2,240,779 11.000% | 2,240,779 (New Position) | Filing History |
| 2020-05-18 5:21 pm Purchase | 2020-05-13 | 13D | Kiniksa Pharmaceuticals, Ltd. KNSA | BAKER BROS. ADVISORS LP | 2,896,777 11.500% | 31,268 (+1.09%) | Filing History |
| 2020-04-10 4:11 pm Sale | 2020-03-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA | ArrowMark Colorado Holdings LLC | 1,274,424 6.300% | -1,009,237 (-44.19%) | Filing History |